As reported in our work, we examined the aberrant expression of VCAM-1, its association with clinicopathological characteristics and patients’ prognosis, and its biological effects on pancreatic cancer in vitro and in vivo. This evidence concerns the gene VCAM1 and familial pancreatic carcinoma.